The notices it replaced
- Reissues: PAR-20-156 Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01 Clinical Trial Optional)
- 2 steps back: PAR-17-032 Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01)
Who won it before
44 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $38,287,268 in first-year total cost, median $793,231.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-6 (J2)]5
- Special Emphasis Panel[ZAG1 ZIJ-6 (J4)]5
- Special Emphasis Panel[ZAG1 ZIJ-6 (M3)]4
- Special Emphasis Panel[ZAG1 ZIJ-6 (O3)]4
- Special Emphasis Panel[ZAG1 ZIJ-6 (M2)]3
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL4
- HUNTER COLLEGE3
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH3
- BOSTON UNIVERSITY MEDICAL CAMPUS2
- CLEVELAND CLINIC LERNER COM-CWRU2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Systematically screening and validating drug repurposing candidates for Alzheimer's Disease and Related Dementias1R56AG084550-01 · under PAR-20-156 | FENG, QIPINGWEI, WEI-QI | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $874,542 | ZAG1 |
| 2024 | Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease1R01AG084531-01 · under PAR-20-156 | LEMERE, CYNTHIA A | BRIGHAM AND WOMEN'S HOSPITAL, MA | $859,410 | ZAG1 |
| 2023 | Harnessing Diverse Bioinformatic Approaches To Repurpose Drugs For Alzheimers Disease And Related Dementias2R01AG058063-06 · under PAR-20-156 | ALBERS, MARK WSORGER, PETER KARL | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,054,706 | ZAG1 |
| 2023 | AI-Powered Quantitative Systems Pharmacology for AD Drug Repurposing2R01AG057555-06 · under PAR-20-156 | XIE, LEI | HUNTER COLLEGE, NY | $693,857 | ZAG1 |
| 2023 | Drugs repositioning to target TREM2 in Alzheimer disease1R01AG081228-01 · under PAR-20-156 | SONG, YUHUA | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $611,134 | ZAG1 |
| 2022 | Develop AD Connectivity Maps with Human iPSC-Derived Brain Cells and their Use1R01AG078164-01 · under PAR-20-156 | HUANG, YADONG | J. DAVID GLADSTONE INSTITUTES, CA | $941,764 | ZAG1 |
| 2022 | TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimers Disease1R01AG076448-01 · under PAR-20-156 | CHENG, FEIXIONGGAN, LIWANG, FEI | CLEVELAND CLINIC LERNER COM-CWRU, OH | $831,528 | ZAG1 |
| 2022 | Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge1R01AG076234-01 · under PAR-20-156 | BIAN, JIANGWANG, FEI | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $807,473 | ZAG1 |
| 2022 | Detecting synergistic effects of pharmacological and non-pharmacological interventions for AD/ADRD1R01AG078154-01 · under PAR-20-156 | XU, HUAZHANG, RUI | UNIVERSITY OF MINNESOTA, MN | $781,522 | ZAG1 |
| 2022 | MWAS+ – A Novel Drug Repurposing Strategy for ADRD Prevention1R01AG073474-01A1 · under PAR-20-156 | AHMED, ALIZAMRINI, EDWARD YZENG, QING | GEORGE WASHINGTON UNIVERSITY, DC | $764,056 | ZAG1 |
| 2022 | The hippocampal dentate gyrus in aging and Alzheimer's disease: boosting transcription of retinoic acid-sensitive genes through vitamin A supplementation and HDAC inhibition1R01AG073826-01A1 · under PAR-20-156 | LAWRENCE, JOHN JOSHUA | TEXAS TECH UNIVERSITY HEALTH SCIS CENTER, TX | $636,809 | ZAG1 |
| 2022 | SmartAD for Intelligent Alzheimer’s Disease(AD) Personalized Combination Therapy1R56AG074951-01A1 · under PAR-20-156 | XIE, XIANG-QUNXUE, YING | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $395,417 | ZAG1 |
| 2021 | Repurposing drugs for Alzheimer´s disease using a reverse translational approach1RF1AG067996-01A1 · under PAR-20-156 | HAGG, SARA | KAROLINSKA INSTITUTE | $1,562,430 | ZAG1 |
| 2021 | Drug repositioning for Alzheimer's disease via genetics, electronic health records, and human iPSC models1R01AG069900-01 · under PAR-17-032 | LI, BINGSHANWEI, WEI-QIWEN, ZHEXING | VANDERBILT UNIVERSITY, TN | $838,304 | ZAG1 |
| 2021 | Translational big data analytic approaches to advance drug repurposing for Alzheimer's disease1R01AG071470-01 · under PAR-20-156 | KIM, DOKYOONNING, XIASHEN, LI | UNIVERSITY OF PENNSYLVANIA, PA | $809,200 | ZAG1 |
| 2021 | Systematic modeling and prediction of cell-type-specific and spatiotemporal crosstalk pathways in Alzheimer's Disease1R01AG071496-01 · under PAR-20-156 | KIM, DOO YEONWONG, STEPHEN TC | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $806,177 | ZAG1 |
| 2021 | Advancing Drug Repositioning for Alzheimer’s Disease using Real-world Data1R56AG069880-01 · under PAR-17-032 | BIAN, JIANGCHEN, YONGWU, YONGHUIXU, HUA | UNIVERSITY OF FLORIDA, FL | $798,718 | ZAG1 |
| 2021 | CICADA: clinical informatics and computational approaches for drug-repositioning of AD/ADRD1R56AG074604-01 · under PAR-20-156 | CHEN, YONGTAO, CUI | UNIVERSITY OF PENNSYLVANIA, PA | $793,964 | ZAG1 |
| 2021 | Advancing drug repositioning and development for Alzheimer's Disease using functional genomics and computational phenomics1R56AG068026-01A1 · under PAR-20-156 | GAMAZON, ERIC R | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $755,981 | ZAG1 |
| 2021 | TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's disease1R01AG069901-01A1 · under PAR-20-156 | ARNOLD, MATTHIASKRUMSIEK, JAN | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $624,944 | ZAG1 |
| 2020 | Compound repositioning for Alzheimer's Disease using knowledge graphs, insurance claims data, and gene expression complementarity1R01AG066750-01 · under PAR-17-032 | SU, ANDREW I | SCRIPPS RESEARCH INSTITUTE, THE, CA | $885,874 | ZAG1 |
| 2020 | Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease1R01AG068030-01 · under PAR-17-032 | BRENNAND, KRISTEN JENNIFERCAI, DONGMINGZHANG, BIN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $845,873 | ZAG1 |
| 2020 | Finding combinatorial drug repositioning therapy for Alzheimer's disease and related dementias1R01AG066749-01 · under PAR-17-032 | JIANG, XIAOQIANZHENG, WENJIN JIM | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $781,522 | ZAG1 |
| 2020 | Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for Alzheimers Disease1R01AG066707-01 · under PAR-17-032 | CHENG, FEIXIONG | CLEVELAND CLINIC LERNER COM-CWRU, OH | $634,650 | ZAG1 |
| 2020 | Combine Genomics and Symptoms Data Driven Models to Discover Synergistic Combinatory Therapies for Alzheimer's Disease1R56AG065352-01A1 · under PAR-17-032 | LI, FUHAI | WASHINGTON UNIVERSITY, MO | $500,322 | ZAG1 |
| 2019 | Big data and small molecules for Alzheimer's disease1RF1AG063913-01 · under PAR-17-032 | GOLDSTEIN, LEE E.XIA, WEIMING | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $2,035,223 | NIA |
| 2019 | Predictive Networks-based in-silico approach for Precision Medicine-repurposing for Alzheimer's Disease1R56AG062620-01 · under PAR-17-032 | BRADSHAW, ELIZABETH MCHANG, RUIKANEKIYO, TAKAHISA | UNIVERSITY OF ARIZONA, AZ | $836,812 | ZAG1 |
| 2019 | The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.1R01AG062547-01 · under PAR-17-032 | HIDE, WINSTON ALEXANDERKIM, DOO YEONTANZI, RUDOLPH EMILE | MASSACHUSETTS GENERAL HOSPITAL, MA | $686,190 | ZAG1 |
| 2019 | Personalized Combination Therapy for AD with Common Comorbidities1R56AG062493-01 · under PAR-17-032 | WANG, LIRONGXIE, XIANG-QUN | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $377,443 | ZAG1 |
| 2018 | SYSTEMATIC DRUG REPURPOSING TARGETING IMMUNE ACTIVATION NETWORKS IN ALZHEIMER'S DISEASE (AD)1RF1AG059319-01 · under PAR-17-032 | EHRLICH, MICHELLE EGANDY, SAMUEL E. | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $4,186,456 | ZAG1 |
| 2018 | Harnessing Diverse BioInformatic Approaches to Repurpose Drugs for Alzheimers Disease1R01AG058063-01A1 · under PAR-17-032 | ALBERS, MARK W | MASSACHUSETTS GENERAL HOSPITAL, MA | $828,046 | ZAG1 |
| 2018 | Quantitative systems pharmacology and translational study of pramlintide for Alzheimer's disease1R56AG059805-01 · under PAR-17-032 | QIU, WEI QIAO WENDY | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $810,558 | ZAG1 |
| 2018 | Drug repurposing for Alzheimer's disease using both observational and chemical genomics data1R56AG059428-01 · under PAR-17-032 | TROPSHA, ALEXANDER | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $794,078 | ZAG1 |
| 2018 | A knowledge map to find Alzheimer's disease drugs1R01AG061105-01 · under PAR-17-032 | LICHTARGE, OLIVIER | BAYLOR COLLEGE OF MEDICINE, TX | $792,498 | ZAG1 |
| 2018 | Phenotypic screening and computational modeling for development of combination therapies for Alzheimer's disease1R56AG059612-01 · under PAR-17-032 | LEZON, TIMOTHY RSCHURDAK, MARK E | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $782,279 | ZAG1 |
| 2018 | Drug repurposing for Alzheimer's disease using structural systems pharmacology.1R01AG057555-01A1 · under PAR-17-032 | XIE, LEI | HUNTER COLLEGE, NY | $779,392 | ZAG1 |
| 2018 | Leveraging the Human Non-Coding Transcriptome to Identify Therapeutics for Healthy Aging and Alzheimers Disease1R56AG061911-01 · under PAR-17-032 | VOLMAR, CLAUDE-HENRYWAHLESTEDT, CLAES ROBERT | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $749,747 | ZAG1 |
| 2018 | Systematic Alzheimer's disease drug repositioning (SMART) based on bioinformatics-guided phenotype screening and image-omics1R01AG057635-01A1 · under PAR-17-032 | WONG, STEPHEN TC | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $694,058 | ZAG1 |
| 2018 | Omic analyses for stratifying Alzheimer's subtypes and identifying novel drug targets1R56AG061163-01 · under PAR-17-032 | CHEN, CHI-HUA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $560,128 | ZAG1 |
| 2018 | A Translational Bioinformatics Approach to Rescuing Synaptic and Neurophysiologic Dysfunction in Alzheimer's Disease1R01AG059854-01 · under PAR-17-032 | TEICH, ANDREW FRANKLIN | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $460,731 | ZAG1 |
| 2017 | ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease1R01AG057683-01 · under PAR-17-032 | HUANG, YADONGSIROTA, MARINA | J. DAVID GLADSTONE INSTITUTES, CA | $875,721 | ZAG1 |
| 2017 | Harnessing Diverse BioInformatic Approaches to Repurpose Drugs for Alzheimer's Disease1R56AG058063-01 · under PAR-17-032 | ALBERS, MARK WSORGER, PETER KARL | MASSACHUSETTS GENERAL HOSPITAL, MA | $835,424 | ZAG1 |
| 2017 | Drug repurposing for Alzheimer's disease using structural systems pharmacology1R56AG057555-01 · under PAR-17-032 | XIE, LEI | HUNTER COLLEGE, NY | $770,770 | ZAG1 |
| 2017 | An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's Disease1R01AG057557-01 · under PAR-17-032 | XU, RONGYAN, RIQIANG | CASE WESTERN RESERVE UNIVERSITY, OH | $541,537 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.